NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma
Updated: May 21, 2022
IFM 99-06
NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma
In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been used since the 1960s and is regarded as the standard of care in elderly patients. We assess whether the addition of thalidomide to this combination or adapted high-dose chemotherapy, using a melphalan 100 mg/m2 -based regimen, would improve survival.
France
Sponsor: University Hospital, Lille
ClinicalTrials.gov Identifier: NCT00367185
Official Title: Comparison of Melphalan-Prednisone(MP),MP-THALIDOMIDE,and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma.
Drug: Thalidomide
Drug: Melphalan
Drug: Prednisone
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Lancet; 2007